Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 5;21:249. doi: 10.1186/s12935-021-01953-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — RAD51 expression predicts platinum sensitivity and survival of ovarian cancer. RAD51 expression was detected immunohistochemically in a cohort of 126 patients and quantified using HSCORE. The patients were subdivided into two groups: HSCORE ≤ 1.5, low expression; HSCORE > 1.5, high expression. Platinum sensitivity was defined as no recurrence within 6 months after therapy, while platinum resistance represented recurrence or relapse within 6 months. a Platinum responsiveness of ovarian cancer patients concerning RAD51 expression was analyzed (Chi-squared test). b Comparison of RAD51 expression between the platinum-sensitive group (N = 92) and the platinum-resistant group (N = 34) (Student’s t-test). Survival analysis was performed and Kaplan–Meier survival curves for OS (c) and PFS (d) were depicted (log-rank test). Correlation analysis between RAD51 expression and mean survival time of patients with the same HSCORE was performed for OS (e) and PFS (f) (Pearson’s correlation test)